⚠️ Heads up: this article is from our "experimental era" — a beautiful mess of enthusiasm ✨, caffeine ☕, and user-submitted chaos 🤹. We kept it because it’s part of our journey 🛤️ (and hey, everyone has awkward teenage years 😅).
Artificial intelligence is poised to revolutionize the biotech sector, potentially bringing an end to years of stock underperformance. According to Hans Peter Portner, who manages Banque Pictet & Cie’s Global Megatrend Selection, the biotech industry is primed for significant catch-up potential, having previously missed out on the investor euphoria that propelled AI stocks to new heights in recent months. This bold prediction suggests a promising future for biotech stocks, as the influence of AI is expected to elevate their performance and redefine their role within the market.